139 related articles for article (PubMed ID: 2960447)
1. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. II. Establishment of tumor-specific immunotherapy models utilizing MDP hapten-reactive helper T cell activity.
Sano H; Kosugi A; Sano S; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1987; 25(3):180-4. PubMed ID: 2960447
[TBL] [Abstract][Full Text] [Related]
2. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemia cells by utilizing MDP hapten-reactive helper T-cell activity.
Shima J; Yoshioka T; Nakajima H; Fujiwara H; Hamaoka T
Cancer Immunol Immunother; 1988; 26(1):43-7. PubMed ID: 2964268
[TBL] [Abstract][Full Text] [Related]
3. The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. I. Synthesis of a novel haptenic MDP derivative cross-reactive with Bacillus Calmette Guerin and its application to enhanced induction of tumor immunity.
Hamaoka T; Takai Y; Kosugi A; Mizushima Y; Shima J; Kusama T; Fujiwara H
Cancer Immunol Immunother; 1985; 20(3):183-8. PubMed ID: 2933141
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system.
Fujiwara H; Aoki H; Yoshioka T; Tomita S; Ikegami R; Hamaoka T
J Immunol; 1984 Jul; 133(1):509-14. PubMed ID: 6233375
[TBL] [Abstract][Full Text] [Related]
5. Cross-reactivity between haptenic muramyl di- or tripeptide derivatives and Mycobacterium bovis BCG: potential application for enhancing tumor immunity.
Kosugi A; Shima J; Sano H; Ogata M; Kusama T; Fujiwara H; Hamaoka T
Infect Immun; 1986 Dec; 54(3):768-73. PubMed ID: 3491048
[TBL] [Abstract][Full Text] [Related]
6. Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism.
Sato S; Fujiwara H; Kosugi A; Hamaoka T
Cancer Immunol Immunother; 1987; 24(2):121-6. PubMed ID: 3493845
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific immunotherapy by active immunization with haptenic muramyl dipeptide derivative-coupled tumor cells.
Fujiwara H; Shima J; Sano H; Kosugi A; Nakajima H; Hamaoka T
Prog Clin Biol Res; 1987; 244():335-44. PubMed ID: 2958872
[TBL] [Abstract][Full Text] [Related]
8. [The augmentation of tumor-specific immunity by T-T cell interaction].
Fujiwara H; Takai Y; Fukuzawa M; Yoshioka T; Izumi Y; Mizushima Y; Qian J; Ogata M; Kosugi A; Nakajima H
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):734-40. PubMed ID: 3157349
[TBL] [Abstract][Full Text] [Related]
9. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
[TBL] [Abstract][Full Text] [Related]
10. [Future perspectives on tumor-specific immunotherapy using hapten-reactive T cell activity].
Hamaoka T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):886-96. PubMed ID: 2786376
[TBL] [Abstract][Full Text] [Related]
11. Effect of helper T cells on prevention of tolerance induction in effector T cells responsible for syngeneic tumor immunity.
Fujiwara H; Kinouchi T; Tsuchida T; Aoki H; Hamaoka T
Gan; 1982 Oct; 73(5):766-72. PubMed ID: 6219908
[TBL] [Abstract][Full Text] [Related]
12. B30-MDP, a synthetic muramyl dipeptide derivative for tumour vaccination to enhance antitumour immunity and antimetastatic effect in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1992; 10(11):792-7. PubMed ID: 1441733
[TBL] [Abstract][Full Text] [Related]
13. Establishment of tumor-specific immunotherapy model utilizing vaccinia virus-reactive helper T cell activity.
Shimizu Y; Hasumi K; Masubuchi K; Okudaira Y
Eur J Immunol; 1988 Nov; 18(11):1773-8. PubMed ID: 2974424
[TBL] [Abstract][Full Text] [Related]
14. Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.
Hamaoka T; Fujiwara H; Teshima K; Aoki H; Yamamoto H; Kitagawa M
J Exp Med; 1979 Jan; 149(1):185-99. PubMed ID: 310858
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers.
Suda T; Fujiwara H; Mizushima Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1986 Dec; 77(6):1267-72. PubMed ID: 2948049
[TBL] [Abstract][Full Text] [Related]
16. Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells.
Takatsu K; Hamaoka T; Tominaga A; Kanamasa Y
J Immunol; 1980 Dec; 125(6):2367-73. PubMed ID: 6776192
[TBL] [Abstract][Full Text] [Related]
17. Effects of hapten epitope structure and hapten-self conjugation pattern on T cell specificity and Ir gene control in hapten-self cytotoxic and helper T cell responses.
Takai Y; Mizuochi T; Fujiwara H; Hamaoka T
J Immunol; 1984 Jan; 132(1):57-62. PubMed ID: 6197460
[TBL] [Abstract][Full Text] [Related]
18. Further study on relationship of anti-tuberculous protection to lung granulomata produced by intravenous injections of synthetic 6-0-mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with or without specific antigens.
Yamamoto K; Kato K; Kakinuma M; Okuyama H; Azuma I
Immunology; 1982 Jun; 46(2):473-9. PubMed ID: 7044961
[TBL] [Abstract][Full Text] [Related]
19. Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses.
Mizushima Y; Fujiwara H; Takai Y; Shearer GM; Hamaoka T
J Natl Cancer Inst; 1985 Jun; 74(6):1269-73. PubMed ID: 3158772
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor growth in mice treated with synthetic muramyl dipeptide.
BubenÃk J; Jezek J; Zaoral M; Hofmann J; Gruntenko YV; Osipov JG; Zolotareva AG; Vakhrusheva TE; Budker VG
Cancer Immunol Immunother; 1984; 18(2):123-5. PubMed ID: 6568871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
